OncXerna Revenue and Competitors

Boston, MA USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • OncXerna's estimated annual revenue is currently $2.2M per year.(i)
  • OncXerna's estimated revenue per employee is $201,000

Employee Data

  • OncXerna has 11 Employees.(i)
  • OncXerna grew their employee count by -59% last year.

OncXerna's People

NameTitleEmail/Phone
1
Head FinanceReveal Email/Phone
2
VP Program Management & Business OperationsReveal Email/Phone
3
VP, QualityReveal Email/Phone
4
Senior Director, Global Clinical OperationsReveal Email/Phone
5
Chief Development Officer & SVP RegulatoryReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$413.3M3240%$634MN/A
#2
$47.8M2380%N/AN/A
#3
$2.4M12-52%N/AN/A
#4
$25.7M12839%N/AN/A
#5
$12.9M64129%N/AN/A
#6
$23.9M1198%$113MN/A
#7
$0.3M30%N/AN/A
#8
$10.3M51-14%N/AN/A
#9
$1.8M367-4%$538MN/A
#10
$50M2493%N/AN/A
Add Company

What Is OncXerna?

Existing precision medicines target just 10 percent of cancers – those with gene mutations or oncogenic drivers for a small number of genes. Oncologie is ushering in a new era of precision medicine, leveraging the company's deep understanding of tumor biology at the RNA level to deliver more effective therapies for many more patients. OncXerna Therapeutics applies its understanding of RNA signatures to describe the dominant biology of the patient's cancer and match it to therapies with mechanisms that modify the dominant biology to dramatically improve patient outcomes.

keywords:N/A

N/A

Total Funding

11

Number of Employees

$2.2M

Revenue (est)

-59%

Employee Growth %

N/A

Valuation

N/A

Accelerator

OncXerna News

2022-04-19 - OncXerna Therapeutics Announces Journal of Clinical ...

OncXerna Therapeutics Announces Journal of Clinical Oncology Publication Featuring Phase 1b Data of Navicixizumab Plus Paclitaxel in Ovarian...

2022-04-13 - OncXerna Therapeutics Highlights the Xerna™ TME Panel's ...

(“OncXerna”) is a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its...

2022-04-06 - Genialis partners with OncXerna to improve targeted therapy

Genialis' ResponderID will use OncXerna's XernaTME (tumor microenvironment) panel to incorporate the pancancer tumor microenvironment...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.8M11-31%$19.6M
#2
$1M11N/AN/A
#3
$1M11N/AN/A
#4
$0.9M11N/AN/A
#5
$0.9M11-8%$11.2M